Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 double-blind randomized placebo-controlled study of intravenous ganaxolone added to standard therapy for refractory status epilepticus
MOH_2023-11-08_013009Phase 3Recruiting
- Sponsor
- Marinus Pharmaceuticals
- Start
- Aug 2023
- Modality
- Allosteric Modulators → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in status epilepticus (SE) comparing Ganaxolone IV + standard of care antiseizure therapy with Placebo IV + standard of care antiseizure therapy (2 arms). Started Aug 2023; status: recruiting.
02
Drugs
ganaxolone
03
Conditions
status epilepticus (SE)
Beyond the preview
Go deeper on MOH_2023-11-08_013009.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2023-11-08_013009.